Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Work In Process: 2023-2024

Historic Work In Process for Tg Therapeutics (TGTX) over the last 2 years, with Dec 2024 value amounting to $68.4 million.

  • Tg Therapeutics' Work In Process rose 62.47% to $121.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.8 million, marking a year-over-year increase of 62.47%. This contributed to the annual value of $68.4 million for FY2024, which is 118.84% up from last year.
  • Tg Therapeutics' Work In Process amounted to $68.4 million in FY2024, which was up 118.84% from $31.2 million recorded in FY2023.
  • Tg Therapeutics' Work In Process' 5-year high stood at $68.4 million during FY2024, with a 5-year trough of $31.2 million in FY2023.
  • In the last 2 years, Tg Therapeutics' Work In Process had a median value of $49.8 million in 2023 and averaged $49.8 million.
  • Data for Tg Therapeutics' Work In Process shows a peak YoY soared of 118.84% (in 2024) over the last 5 years.
  • Tg Therapeutics' Work In Process (Yearly) stood at $31.2 million in 2023, then skyrocketed by 118.84% to $68.4 million in 2024.